TriangleNCT00028002 · OUTCOME
Rates of Objective Response (Complete, Partial, and Stable)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Pretreatment and prior to surgery (at 4-10 weeks, based on surgery timing)
What was measured
The percentage of patients who achieved a complete, partial or stable response prior to surgery as assessed by Response Evaluation Criteria in Solid Tumours criteria (RECIST). RECIST criteria is described here: http://ctep.cancer.gov/protocolDevelopment/docs/recist\_guideline.pdf.
Analysis population: Eligible patients who started study treatment
Groups in this outcome
Imatinib Mesylate
Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
| Group | Source count |
|---|---|
| Imatinib Mesylate | 52 |
Reported measurements
Complete Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Imatinib Mesylate | 0 | Not reported | 0 | 0 | Not reported |
Partial Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Imatinib Mesylate | 5.8 | Not reported | 1.2 | 15.9 | Not reported |
Stable Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Imatinib Mesylate | 86.5 | Not reported | 74.2 | 94.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- title
- Complete Response
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.2
- upper Limit
- 15.9
- value
- 5.8
- title
- Partial Response
- categories
- measurements
- group Id
- OG000
- lower Limit
- 74.2
- upper Limit
- 94.4
- value
- 86.5
- title
- Stable Disease
- denoms
- counts
- group Id
- OG000
- value
- 52
- units
- Participants
- description
- The percentage of patients who achieved a complete, partial or stable response prior to surgery as assessed by Response Evaluation Criteria in Solid Tumours criteria (RECIST). RECIST criteria is described here: http://ctep.cancer.gov/protocolDevelopment/docs/recist\_guideline.pdf.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
- id
- OG000
- title
- Imatinib Mesylate
- param Type
- NUMBER
- population Description
- Eligible patients who started study treatment
- reporting Status
- POSTED
- time Frame
- Pretreatment and prior to surgery (at 4-10 weeks, based on surgery timing)
- title
- Rates of Objective Response (Complete, Partial, and Stable)
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice